Skip to main content

Table 2 Correlation between WT1 expression and clinicopathological factors

From: Prognostic significance of WT1 expression in soft tissue sarcoma

Clinicopathologic parameters WT-1 protein expression
  Absent, n = 40 (46.0%) Present, n = 47 (54.0%) P value
Age    
 <50 19 (47.5) 21 (52.5) 0.793
 >50 21 (44.7) 26 (55.3)  
Histologic type    
 Liposarcoma 20 (76.9) 6 (23.1) 0.005
 MFH 9 (42.9) 12 (57.1)  
 Leiomyosarcoma 2 (33.3) 4 (66.7)  
 Rhabdomyosarcoma 1 (8.3) 11 (91.7)  
 MPNST 2 (28.6) 5 (71.4)  
 Synovial sarcoma 3 (42.9) 4 (57.1)  
 Fibrosarcoma 1 (20.0) 4 (80.0)  
 Others 2 (40.0) 3 (60.0)  
Size    
 <5 cm 3 (23.1) 10 (76.9) 0.072
 >5 cm 37 (50.0) 37 (50.0)  
Metastasis at Dx    
 Absent 38 (45.8) 45 (54.2) 0.869
 Present 2 (50.0) 2 (50.0)  
FNCLCC grade    
 1 16 (94.1) 1 (5.9) 0.000
 2 14 (37.8) 23 (62.2)  
 3 10 (30.3) 23 (69.7)  
Modified grade *    
 Low 16 (94.1) 1 (5.9) 0.000
 High 24 (34.3) 46 (65.7)  
AJCC stage    
 1 15 (83.3) 3 (16.7) 0.003
 2 14 (34.1) 27 (65.9)  
 3 9 (36.0) 16 (64.0)  
 4 2 (66.7) 1 (33.3)  
AJCC modified**    
 Localized 15 (83.3) 3 (16.7) 0.000
 Advanced 25 (36.2) 44 (63.8)  
  1. *FNCLCC grade was divided into 2 groups, low grade including FNCLCC group 1 and high grade including FNCLCC grade 2 and 3.
  2. **AJCC stage 1 was defined as localized disease and AJCC stage 2, 3, and 4 were defined as advanced disease.
  3. MFH, Malignant fibrous histiocytoma; MPNST, Malignant peripheral nerve sheath tumor; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; AJCC, American Joint Committee on Cancer.